Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Merck KGaA
- Pfizer
This publication has 21 references indexed in Scilit:
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trialThe Lancet Oncology, 2017
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2017
- A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorBritish Journal of Cancer, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint BlockadeImmunity, 2016
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEuropean Journal of Cancer, 2014
- Pancreatic cancer: why is it so hard to treat?Therapeutic Advances in Gastroenterology, 2013
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 InhibitorCancer Research, 2010
- Cancer phase I clinical trials: efficient dose escalation with overdose controlStatistics in Medicine, 1998